We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Image: Market growth is also supported by advances in diagnostics and life sciences research, including more sensitive multiplex platforms, improved assay chemistry, and greater laboratory automation (image creMarket growth is also supported by advances in diagnostics and life sciences research, including more sensitive multiplex platforms, improved assay chemistry, and greater laboratory automation (image credit: Shutterstock)

Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand

The global multiplex assays market is projected to grow from USD 7.15 billion in 2026 to USD 10.65 billion by 2031. More...
01 Jun 2026
Image: New findings shows that specific blood proteins are altered long before multiple sclerosis diagnosis, pointing to a potential approach for pre-symptomatic risk assessment (image credit: Adobe Stock)

Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis

Researchers identify plasma proteins altered years before MS, supporting pre-symptomatic risk stratification and prognosis. More...
01 Jun 2026
Image: Leica Biosystems and CellCarta have expanded a coordinated companion diagnostic (CDx) development model to biopharma sponsors worldwide

Global Framework Integrates Digital Pathology for Companion Diagnostic Development

Leica Biosystems and CellCarta have expanded a coordinated CDx development model to biopharma sponsors worldwide. More...
01 Jun 2026
Image: NHS-Galleri Trial: Percent difference in Stage IV cancers (Photo courtesy of GRAIL)

GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026

GRAIL reported NHS-Galleri trial findings at ASCO 2026 showing fewer stage IV diagnoses despite missing the combined stage III–IV endpoint. More...
01 Jun 2026
Image: Tempus AI has upgraded its smart physician platform, Tempus Hub, with a next-generation generative AI clinical co-pilot for healthcare providers (Photo courtesy of Tempus AI)

Agentic AI Platform Supports Genomic Decision-Making in Oncology

A new system embeds agentic AI to surface guideline-matched oncology therapies and auto-generate patient documentation. More...
01 Jun 2026
Image: NHS-Galleri Trial: Percent difference in Stage IV cancers (Photo courtesy of GRAIL)

MCED Blood Test Reduces Stage IV Cancer Diagnoses in NHS Trial

GRAIL reported NHS-Galleri trial findings at ASCO 2026 showing fewer stage IV diagnoses despite missing the combined stage III–IV endpoint. More...
31 May 2026
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

New findings identify an immune "energy signature" that distinguishes latent from active TB and may signal treatment response. More...
29 May 2026
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Rapid Sepsis Test
SeptiCyte RAPID
Copyright © 2000-2026 Globetech Media. All rights reserved.